Key terms
About CRBP
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CRBP news
Yesterday
8:42am ET
Corbus Pharmaceuticals Financial Performance Update Insights
Yesterday
8:04am ET
Corbus Pharmaceuticals reports Q1 EPS (83c) vs ($4.24) last year
Apr 19
11:12am ET
Biotech Alert: Searches spiking for these stocks today
Apr 18
11:18am ET
Biotech Alert: Searches spiking for these stocks today
Apr 08
8:30am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Apr 04
5:55am ET
Corbus Pharmaceuticals management to meet with Oppenheimer
Apr 02
8:10am ET
Corbus announces dosing of first patient in Phase 1 trial of CRB-701
Apr 02
4:55am ET
Corbus Pharmaceuticals management to meet with Oppenheimer
Mar 28
10:36am ET
Corbus Pharmaceuticals management to meet with Oppenheimer
Mar 27
4:55am ET
Corbus Pharmaceuticals management to meet with Oppenheimer
Mar 25
7:48am ET
Corbus Pharmaceuticals management to meet with Oppenheimer
Mar 13
4:53pm ET
Corbus Pharmaceuticals files $300M mixed securities shelf
Mar 13
7:26am ET
Corbus Pharmaceuticals price target raised to $58 from $51 at Oppenheimer
Mar 12
8:32am ET
Corbus Pharmaceuticals Shares Informal Financial Snapshot
Mar 12
8:04am ET
Corbus Pharmaceuticals sees cash runway through March 31, 2027
Mar 12
8:04am ET
Corbus Pharmaceuticals reports Q4 EPS ($1.81) vs. ($2.61) last year
Mar 06
8:30am ET
One new option listing on March 6th
Mar 06
7:54am ET
Corbus Pharmaceuticals upgraded to Buy from Hold at Jefferies
Feb 28
8:05am ET
Corbus Pharmaceuticals appoints Smethurst as CMO
No recent press releases are available for CRBP
CRBP Financials
Key terms
Ad Feedback
CRBP Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CRBP Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
